Mark Vanden Avond

Mr. Mark Vanden Avond

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2023 in EBioMedicine
Verified
Journal Article
Open access
MLMichael W. Lawlor
Michael W. Lawlor
BSBenedikt Schoser
Benedikt Schoser
MMMarta Margeta
Marta Margeta
CSCaroline A. Sewry
Caroline A. Sewry
KJKarra A. Jones
Karra A. Jones
SRSalvador Rico
Salvador Rico
X-linked myotubular myopathy (XLMTM) is a rare, life-threatening congenital muscle disease caused by mutations in the MTM1 gene that result in profound muscle weakness, significant respiratory insufficiency, and high infant mortality. There is no approved disease-modifying therapy for XLMTM. Resamirigene bilparvovec (AT132; rAAV8-Des-hMTM1) is an investigational adeno-associated virus (AAV8)-mediated gene replacement therapy designed to deliver MTM1 to skeletal muscle cells and achieve long-term correction of XLMTM-related muscle pathology. The clinical trial ASPIRO (NCT03199469) investigating resamirigene bilparvovec in XLMTM is currently paused while the risk:benefit balance associated with this gene therapy is further investigated. Muscle biopsies were taken before treatment and 24 and 48 weeks after treatment from ten boys with XLMTM in a clinical trial of resamirigene bilparvovec (ASPIRO; NCT03199469). Comprehensive histopathological analysis was performed. Baseline biopsies uniformly showed findings characteristic of XLMTM, including small myofibres, increased internal or central nucleation, and central aggregates of organelles. Biopsies taken at 24 weeks post-treatment showed marked improvement of organelle localisation, without apparent increases in myofibre size in most participants. Biopsies taken at 48 weeks, however, did show statistically significant increases in myofibre size in all nine biopsies evaluated at this timepoint. Histopathological endpoints that did not demonstrate statistically significant changes with treatment included the degree of internal/central nucleation, numbers of triad structures, fibre type distributions, and numbers of satellite cells. Limited (predominantly mild) treatment-associated inflammatory changes were seen in biopsy specimens from five participants. Muscle biopsies from individuals with XLMTM treated with resamirigene bilparvovec display statistically significant improvement in organelle localisation and myofibre size during a period of substantial improvements in muscle strength and respiratory function. This study identifies valuable histological endpoints for tracking treatment-related gains with resamirigene bilparvovec, as well as endpoints that did not show strong correlation with clinical improvement in this human study. Astellas Gene Therapies (formerly Audentes Therapeutics, Inc.).

6 July 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
RSRebecca A. Slick
Rebecca A. Slick
JTJennifer A. Tinklenberg
Jennifer A. Tinklenberg
JSJessica Sutton
Jessica Sutton
LZLiwen Zhang
Liwen Zhang
HMHui Meng
Hui Meng
MLMichael W. Lawlor
Michael W. Lawlor

5 July 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
JTJennifer A. Tinklenberg
Jennifer A. Tinklenberg
RSRebecca A. Slick
Rebecca A. Slick
JSJessica Sutton
Jessica Sutton
LZLiwen Zhang
Liwen Zhang
HMHui Meng
Hui Meng
MLMichael W. Lawlor
Michael W. Lawlor

22 February 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
DJDavid C. Jewett
David C. Jewett
DLDonisha Shani Niharika Keembiya Liyanagamage
Donisha Shani Niharika Keembiya Liyanagamage
MAMark Vanden Avond
Mark Vanden Avond
MAMolly AB Anderson
Molly AB Anderson
KTKyleigh A. Twaroski
Kyleigh A. Twaroski
ALAllen Stuart Levine
Allen Stuart Levine
The opioid antagonist naltrexone (NTX) decreases intake of preferred diets in rats at very low doses relative to doses needed to decrease intake of “bland” laboratory chow. In the absence of an opioid agonist, NTX is not discriminable using operant techniques. In the current study, we found that rats given intermittent access to a 25% sucrose solution learned to discriminate between various naltrexone doses and saline. None of the rats given only water learned to discriminate between naltrexone and saline. When access to the sucrose solution was discontinued for 14 days, the rats lost the ability to discriminate between NTX and saline. We also studied the changes of c-Fos IR in selected brain regions in rats treated with saline versus NTX that were drinking water or 25% sucrose. An injection of NTX or saline resulted in a significant drug, diet, and interaction effect in various brain regions associated with feeding behavior, particularly the amygdala, accumbens, and hypothalamic sites. Thus, we found that ingestion of a sucrose solution results in the ability of rats to reliably discriminate naltrexone administration. In addition, sucrose and naltrexone altered c-Fos IR in an interactive fashion in brain regions known to be involved in ingestion behavior.

13 August 2026 in Science
Verified
Journal Article
Closed access
QQQiongzi Qiu
Qiongzi Qiu
YLYong Liu
Yong Liu
HXHong Xue
Hong Xue
RPRajan Pandey
Rajan Pandey
JLJing Liu
Jing Liu
MLMingyu Liang
Mingyu Liang
Hypertension is a leading cause of disease burden and mortality. Here, we present a single-cell analysis of hypertension and end-organ damage across six organs and tissues in angiotensin II–treated mice, Dahl salt–sensitive rats, and spontaneously hypertensive rats. We identified gene programs associated with blood pressure and renal injury, including a conserved vascular smooth muscle cell program and cross-segment renal tubular programs, along with tissue-specialized endothelial adaptations and coordinated changes across cell types in select organs. Integration with human genomic data revealed model-specific and shared cell type–trait links. We prioritized a noncoding variant (rs28451064) and used genome editing to demonstrate its in vivo effect on blood pressure and allele-specific regulation of local genes. Our study provides a multimodel, cross-organ cellular resource for hypertension research.

1 November 2026 in Physiological Genomics
Verified
Journal Article
Open access
MAMark Vanden Avond
Mark Vanden Avond
MGMichael N. Grzybowski
Michael N. Grzybowski
TKTerry Kurth
Terry Kurth
CYChun Yang
Chun Yang
JKJason Klotz
Jason Klotz
AGAron Geurts
Aron Geurts
We mutated a noncoding DNA-binding site for a chromatin architectural protein near a gene critical for blood pressure regulation in the Dahl salt-sensitive rat. This mutation altered chromatin organization, gene expression, and blood pressure, providing the first evidence that disruption of a single regulatory site is sufficient to influence blood pressure in a sex-specific manner. This highlights how chromatin conformation may be altered by noncoding variants to exert whole animal physiological effects.